Discover a recent study from 12 hospitals across China that has shed new light on personalised care for plaque psoriasis.

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

A very large percentage of all of these patient segments are currently ... of ZORYVE foam to help patients with scalp and ...

1 "People who have special site plaque psoriasis with lesions that cover ... scalp psoriasis clearance in people of color in new large phase 3b study. Johnson & Johnson. News release.

moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment. Data from the Phase 3b SPECTREM study to measure skin clearance and other treatment outcomes in low ...

1 Data from the Phase 3b SPECTREM study, the first prospective, large-scale ... "People who have special site plaque psoriasis with lesions that cover a smaller total area of their body are ...

Stationary plaque psoriasis, which is usually a chronic illness ... distal interphalangeal [DIP] arthritis), but sometimes also individual large joints (oligoarthritis). About 40% of patients ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...

Statistically significant improvements were also achieved across all major secondary endpoints, including: 52.9% achieved a Psoriasis Area ... a chronic disease of the large intestine in which ...

Additional interested parties are encouraged to schedule a meeting through the conference partnering platform or to email Scinai at [email protected] to schedule a meeting. Throughout the conference, ...

J&J evaluated its Tremfya in patients with low body surface area moderate plaque psoriasis with special ... The SPECTREM study is the first large-scale trial to measure skin clearance and other ...